Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H), a Canadian oncology company, is advancing its preclinical candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms that enable cancer survival and treatment resistance. The company reported completing a 300-gram API scale-up with approximately 99.3% purity, a key milestone for clinical translation. This achievement supports the company's efforts to build the manufacturing, regulatory, and financial infrastructure necessary for clinical development.
Manufacturing capabilities have been expanded through a partnership with Nanosoft Polymers. Additionally, Onco-Innovations is progressing metabolism, analytical, licensing, and other IND-enabling activities. These steps are critical for preparing an Investigational New Drug (IND) application, which is required before initiating human trials. The company has also arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches, to support ONC010 development, the SynoGraph platform, and general corporate needs. The company notes that eventual proceeds may differ from the stated notional amount.
The appointment of Dave Antony as Chief Financial Officer adds financial and corporate experience as the company continues IND-enabling work toward a planned Phase 1 study of ONC010 in Australia. For more details, the full article is available at https://nnw.fm/YPLe7. Onco-Innovations is dedicated to cancer research and treatment through pioneering research and innovative solutions, and has secured an exclusive worldwide license to patented technology targeting solid tumours. The company's website is https://oncoinnovations.com/.
This news matters because it signals tangible progress in developing a novel cancer therapy. ONC010's approach of inhibiting PNKP to disrupt DNA repair could potentially overcome treatment resistance, a major challenge in oncology. The successful scale-up and purity level demonstrate manufacturing feasibility, while the financing provides runway to advance toward clinical trials. If ONC010 proves safe and effective in humans, it could offer a new option for patients with solid tumours. The planned Phase 1 study in Australia will be an important early test of the drug's potential.
For investors, the news provides updates on milestones. The latest updates are available in the company's newsroom at https://nnw.fm/ONNVF. NetworkNewsWire, a specialized communications platform, disseminated this announcement. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. Full terms of use and disclaimers are on the NetworkNewsWire website at https://www.NetworkNewsWire.com/Disclaimer.
